

## Highly Diastereoselective Ring Chain Transformation of Butenolides to 5-( $\alpha$ -Hydroxyalkyl)pyrazolidin-3-ones<sup>1</sup>

Jörg Bohrisch<sup>a</sup>, Michael Pätzel<sup>a</sup>, Jürgen Liebscher<sup>a</sup>, Peter G. Jones<sup>b</sup>


- <sup>a</sup> Fachbereich Chemie, Humboldt-Universität Berlin, Hessische Str. 1-2, D-1040 Berlin, Germany.
- <sup>b</sup> Institut für Anorganische und Analytische Chemie, Technische Universität Braunschweig, Hagenring 30, D-3300 Braunschweig, Germany.

**Abstract:** Butenolides **1** react with hydrazines **2** by a novel ring chain transformation to 5-( $\alpha$ -hydroxyalkyl)pyrazolidin-3-ones **4** via intermediate 4-hydrazinobutyrolactones **3** in a highly diastereoselective manner.

Ring chain transformations with bridged 1,3-dicarbonyl heteroanalogues represent a useful method for the synthesis of a variety of  $\omega$ -aminoalkylheteroaromatics.<sup>2,3</sup> For example, 2-arylmethylidenepyrrolidines or corresponding 3-chloropropeniminium salts react as 1,3-bi-electrophiles with hydrazine giving  $\omega$ -aminopropylpyrazoles.<sup>3</sup>

We became interested in extending this concept to bridged  $\alpha,\beta$ -unsaturated carbonyl compounds as reactants in order to synthesize partially saturated heterocycles in a stereoselective manner.

As a first example we report a ring chain transformation of butenolides **1** with hydrazines **2**. If hydrazine or methylhydrazine **2** ( $R^2 = H$  or  $CH_3$ ) is reacted with butenolides **1** in a polar solvent 5-( $\alpha$ -hydroxyalkyl)pyrazolidin-3-ones **4** are obtained in high chemical yields and high diastereomeric excess. If the enantiomerically pure starting material **1** ( $R^1 = CH_2OH$ ) was used, only one optical isomer **4c** was isolated. Usually traces of 4-hydrazinobutyrolactones **3** are found in the reaction mixture. Kinetic studies (to be reported elsewhere) revealed that these compounds **3** act as intermediates in the formation of the pyrazolidinones **4**. Consequently, the transformation of the butenolides **1** to 5-( $\alpha$ -hydroxyalkyl)pyrazolidin-3-ones **4** starts with the addition of the hydrazine **2** to the C-C double bond of the  $\alpha,\beta$ -unsaturated system **1**. Subsequent attack of the second amino group of the hydrazine moiety at the carbonyl group of the lactone intermediate **3** results in a ring cleavage giving the products **4**. If phenylhydrazine **2** ( $R^1 = \text{phenyl}$ ) is used, an addition product (**5**) can again be observed, but the latter reacts with a second molecule of phenylhydrazine by cleaving the exocyclic



i.  $\text{H}_2\text{O}$ , 2h,  $80^\circ\text{C}$ . ii. DMAP, TosCl, pyridine, 2h. iii.  $\text{H}_2\text{O}$ , 10 min,  $80^\circ\text{C}$ . iv. ethyl acetate, 3d, r.t..

C-O bond, giving a 4-phenylhydrazinotetrahydrofuran-2-hydrazone **6**, rather than undergoing a ring chain transformation. Nevertheless this result is also interesting since reaction of butenolides with two molecules of amines is known to give ring-opened 4-aminobutanamides<sup>4</sup> rather than 4-aminotetrahydrofuran-2-imines.




Fig. 1: X-Ray structural analysis of 4b<sup>5</sup>

**Table 1: Preparation of 5-( $\alpha$ -hydroxyalkyl)pyrazolidin-3-ones **4**, 4-phenylhydrazinobutyro-lactone **5**, and 4-phenylhydrazinotetrahydrofuran-2-hydrazone **6****

	R <sup>1</sup>	R <sup>2</sup>	yield / %	ratio of diastereomers
<b>4a</b> <sup>2)</sup>	Me	H	63	86 : 14 <sup>1)</sup>
<b>4b</b> <sup>3)</sup>	Me	Tos	75	94 : 6 <sup>1)</sup>
<b>4c</b>	CH <sub>2</sub> OH (S)	H	72	>95 : 5
<b>4d</b>	CH <sub>2</sub> OH (S)	Tos	30	>95 : 5
<b>4e</b>	Me	Me	61	>95 : 5 <sup>1)</sup>
<b>5a</b> <sup>4)</sup>	Me	Ph	15	>95 : 5 <sup>1)</sup>
<b>6a</b> <sup>5)</sup>	Me	Ph	18	90 : 10 <sup>1)</sup>

<sup>1)</sup> racemic

<sup>2)</sup> <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm ; J / Hz : 1.03 (d, 3H, J = 6)CH<sub>3</sub>; 2.21 (dd, 1H, J<sub>1</sub> = 16, J<sub>2</sub> = 7)CH<sub>2</sub>; 2.30 (dd, 1H, J<sub>1</sub> = 16, J<sub>2</sub> = 7)CH<sub>2</sub>; 3.20 (q, 1H, J = 7)CH-N; 3.51 (p, 1H, J = 6) CH-O; 8.91; (sb, 1H)NH  
<sup>13</sup>C-NMR (75 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm : 20.8 (CH<sub>3</sub>); 33.2 (CH<sub>2</sub>); 63.0 (CH-N); 66.0 (CH-O); 175.6 (C=O)

<sup>15</sup>N-NMR (30 MHz, D<sub>2</sub>O);  $\delta$  / ppm : 78.9 (NH-CH); 140.0 (NH-CO)

<sup>3)</sup> <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm ; J / Hz : 1.11 (d, 3H, J = 6)CH<sub>3</sub>; 1.22 (dd, 1H, J<sub>1</sub> = 17, J<sub>2</sub> = 9)CH<sub>2</sub>; 1.99 (d, 1H, J = 17)CH<sub>2</sub>; 2.42 (s, 3H)Ph-CH<sub>3</sub>; 3.54 (p, 1H, J = 6)CH-O; 3.78 (t, 1H, J = 7)CH-N; 5.07 (d, 1H, J = 6)OH; 7.48 (d, 2H, J = 8)CH<sub>arom</sub>; 7.74 (d, 2H, J = 8)CH<sub>arom</sub>; 10.73 (s, 1H)NH  
<sup>13</sup>C-NMR (75 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm : 20.1 (CH<sub>3</sub>); 21.2 (CH<sub>2</sub>); 29.7 (CH<sub>2</sub>); 64.7 (CH-N); 67.1 (CH-O); 129.0 (CH<sub>arom</sub>); 130.2 (CH<sub>arom</sub>); 130.2 (C<sub>arom</sub>); 145.4 (C<sub>arom</sub>); 174.3 (C=O)  
 m.p. : 206-8 °C

<sup>4)</sup> <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm ; J / Hz : 1.25 (d, 3H, J = 7)CH<sub>3</sub>; 2.30 (dd, 1H, J<sub>1</sub> = 18, J<sub>2</sub> = 3)CH<sub>2</sub>; 2.82 (dd, 1H, J<sub>1</sub> = 18, J<sub>2</sub> = 7)CH<sub>2</sub>; 3.37 (m, 1H)CH-N; 4.45 (qd, 1H, J<sub>1</sub> = 7, J<sub>2</sub> = 2)CH-O; 4.82 (sb 1H)NH; 6.90 (m, 5H)Ph; 7.62 (sb, 1H)NH-Ph  
<sup>13</sup>C-NMR (75 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm : 19.0 (CH<sub>3</sub>); 32.6 (CH<sub>2</sub>); 60.9 (CH-N); 79.6 (CH-O); 111.8 (CH<sub>arom</sub>); 117.2 (CH<sub>arom</sub>); 128.7 (CH<sub>arom</sub>); 145.4 (C<sub>arom</sub>); 150.5 (C<sub>arom</sub>); 176.1 (C=O)  
 m.p. : 112-4 °C

<sup>5)</sup> <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm ; J / Hz : 1.12 (d, 3H, J = 7)CH<sub>3</sub>; 2.72 (dd, 1H, J<sub>1</sub> = 14, J<sub>2</sub> = 3)CH<sub>2</sub>; 2.90 (dd, 1H, J<sub>1</sub> = 14, J<sub>2</sub> = 9)CH<sub>2</sub>; 4.06 (m, 2H)CH-N, CH-O; 5.02 (d, 1H)NH; 6.52 (m, 3H)CH<sub>arom</sub>; 6.82 (m, 2H)CH<sub>arom</sub>; 7.60 (m, 6H)CH<sub>arom</sub>, NH; ); 9.69 (d, 1H, J = 3)NH  
<sup>13</sup>C-NMR (75 MHz, DMSO-*d*<sub>6</sub>, TMS);  $\delta$  / ppm : 20.4 (CH<sub>3</sub>); 33.5 (CH<sub>2</sub>); 67.5 (CH-N); 80.0 (CH-O); 112.0 (CH<sub>arom</sub>); 118.0 (CH<sub>arom</sub>); 122.1 (CH<sub>arom</sub>); 128.3 (CH<sub>arom</sub>); 129.1 (CH<sub>arom</sub>); 130.7 (CH<sub>arom</sub>); 149.1 (C<sub>arom</sub>); 151.4 (C<sub>arom</sub>); 170.1 (C=O)  
 m.p. : 135-7 °C

The non tosylated products **4** appeared as oils. Their spectroscopic data are in full agreement with the proposed structures. The regioselectivity of the reaction of methylhydrazine **2** (R<sup>2</sup> =

CH<sub>3</sub>) with the butenolide **1** (R<sup>1</sup> = Me) could be proved by NOE difference <sup>1</sup>H-NMR experiments demonstrating the proximity of R<sup>2</sup>(CH<sub>3</sub>) and the CHOH moiety in the final product **4a**. The relative stereochemistry of the substituents at both chiral centers could be proved by transforming the N-unsubstituted pyrazolidin-3-one **4a** to the crystalline 1-tosyl derivative **4b** and X-ray crystal structure analysis.<sup>5</sup> The relative configuration (ul) at the two asymmetric carbon atoms implies an approach of the hydrazine **2** to the C-C double bond of **1** from the less hindered side, viz. opposite the substituent R<sup>1</sup>. A similar stereochemical pathway is reported in the addition of amines to butenolides<sup>4</sup> and pentenolides.<sup>6</sup>

The extension of the ring chain transformation principle to other bridged 1,3-bielectrophiles (e. g. pentenolides<sup>6</sup> or  $\alpha,\beta$ -unsaturated lactams) or other binucleophiles is currently under way. Recently the ring chain transformation of pentenolides with hydroxylamines was reported.<sup>7,8</sup>

**Acknowledgement** - We thank the Verband der Chemischen Industrie for financial support, Dr. Mügge and Mr. Bloedorn for detailed NMR investigations

#### References and Notes

1. Ring Chain Transformations Part XIII, Part XII see: Pätzelt, M.; Knoll, A.; Steincke, T.; von Löwis, M.; Liebscher, J. *J. Prakt. Chem./Chem. Ztg.* in press.
2. Bohrisch, J.; Pätzelt, M.; Liebscher, J.; Maas, G. *Synthesis* in press.
3. Bohrisch, J.; Pätzelt, M.; Liebscher, J. *Synthesis* (1991), 1153.
4. Jones, J. B.; Young, J. M. *Can. J. Chem.* (1966) **44**, 1059.
5. Compound **4b** (C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S) crystallises in the triclinic space group P1 with  $a = 6.562(3)$ ,  $b = 10.352(6)$ ,  $c = 10.699(6)$  Å,  $\alpha = 110.25(3)$ ,  $\beta = 96.91(3)$ ,  $\gamma = 95.34(3)^\circ$ ,  $U = 669.8 \text{ \AA}^3$  (at -130°C),  $Z = 2$ , Mo-K $\alpha$  radiation,  $2\theta_{\text{max}} 50^\circ$ . The structure was solved by direct methods and refined anisotropically on  $F^2$  (all 2354 independent reflections, H atoms using a riding model) to  $wR (F^2)$  0.080 (conventional  $R(F)$  0.033). Program system: SHELXS/L-92. Full details have been deposited at the Fachinformationszentrum Karlsruhe, Gesellschaft für Wissenschaftlich-technische Information mbH, D-7514 Eggenstein-Leopoldshafen 2, Federal Republic of Germany. Any request for this material should quote a full literature citation and the reference number CSD 56913.
6. Yoda, H.; Shirai, T.; Kawasaki, T.; Katagiri, T.; Takabe, K.; Kimata, K.; Hosoya, K. *Chem. Lett.* (1991), 793.
7. Maciejewski, S.; Panfil, I.; Belzecki, C.; Chmielewski, M. *Tetrahedron* (1992) **48**, 10363.
8. Panfil, I.; Maciejewski, S.; Belzecki, C.; Chmielewski, M. *Tetrahedron Lett.* (1989) **30**, 1527.

(Received in Germany 22 December 1992)